A compound or a pharmaceutically acceptable salt of Formula I； Wherein L is C1-6 alkyl optionally substituted with one or more fluoro； X is O or S； each R1 is independently halo, Ra1, -CN, -Aa1-C(Qa1)Rb1, -Ab1-C(Qb1)N(Rc1)Rd1, -Ac1-C(Qc1)ORe1, -Ad1-S(O)pRf1, -Ae1S(O)pN(Rg1)Rh1, -Af1-S(O)pORi1, -N3, -N(Rj1)Rk1, -N(H)CN, -NO2, -ONO2, ORl1 or SRm1； each Qa1-Qc1 is independently =O, =S, =NRn1, =N(ORo1)； each Aa1-Af1 is independently –N(Rp1)- or –O-； n is 0-4； each p is 1-2； R2 is -C(O)ORa2, -C(O)NRb2Rc2 or tetrazole； wherein Ra1-Rp1 and Ra2-Rc2 are as defined herein； provided the compound is not (6-chloro-5,7-dimethyl-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl) acetic acid or 3-(6-chloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl) propanoic acid). The compounds, including those covered by the proviso, are disclosed to be useful in the treatment of neurodegenerative and neuroinflammatory diseases. The use of the compound in combination products and kits-of-parts comprising one or more other therapeutic agent useful in the treatment of neurodegenerative and neuroinflammatory diseases is also disclosed.L'invention concerne des composés de formule (I) ou des sels pharmaceutiquement acceptables de ceux-ci. Dans la formule (I), X, Y, Z, R1 et R2 sont tels que décrits dans la description. Lesdits composés sont utiles dans le traitement de maladies neurodégénératives et neuro-inflammatoires.
